Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease

25 May 2013

Abstract excerpt

BACKGROUND: The apolipoprotein E (APOE) ε4 genotype has been recommended as a potential inclusion or exclusion criterion in targeted clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) resulting from AD, and has been implemented in trials of immunotherapeutic agents. METHODS: We tested this recommendation with clinical trial simulations using participants from a meta-database of 19...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Computational Drug Discovery Methods
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23712001
DOI: 10.1016/j.jalz.2013.03.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseasePMID 23712001Read ↗

The APOE genotype: modification of therapeutic responses in Alzheimer's disease.Semantic proximity Read ↗

Age‐dependent effects of <i>APOE</i> ε4 in preclinical Alzheimer's diseaseSemantic proximity Read ↗

<i>APOE</i> ε4: The most prevalent yet understudied risk factor for Alzheimer's diseaseSemantic proximity Read ↗

Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis.Semantic proximity Read ↗

Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis.Semantic proximity Read ↗

The effect of the APOE4 genotype on physiological and cognitive health in randomised controlled trials with an exercise intervention: a systematic review and meta-analysisSemantic proximity Read ↗

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled studySemantic proximity Read ↗

Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentSemantic proximity Read ↗

Choosing Alzheimer's disease prevention clinical trial populations.Semantic proximity Read ↗

Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.Semantic proximity Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.